Multiple sclerosis (MS) is an autoimmune disorder that impacts the spinal cord and brain. MS presents in various forms, including relapsing-remitting MS (RRMS) or primary progressive MS (PPMS).
Technology Description: Ocrelizumab (Ocrevus) is a humanized monoclonal antibody therapy that is directed toward cluster of differentiation (CD)20, which is a B-cell surface molecule. Ocrelizumab exerts its immunomodulatory effect by selectively depleting CD20-expressing B cells, which may provide therapeutic benefit in immune disorders such as RRMS and PPMS.
Clinical Alternatives: There are several alternative disease-modifying therapies for MS, including beta interferons, glatiramer acetate, fingolimod, and natalizumab.
If you have a Hayes login, click here to view the full report on the Knowledge Center.